Again to Journals » OncoTargets and Therapy » Volume 15

Wang J, Li H, Xia C, et al. Onco Targets Ther. 2019;12:869–882.

The authors have suggested Determine 2E on web page 874 is inaccurate. As a result of an error on the time of determine meeting NC (24 h) and shCENPK (48 h) within the SMMC-7721 row had been inadvertently duplicated. The right Determine 2 is as follows.

Determine 2 Silencing of CENPK inhibits HCC cell development, migration, and invasion in vitro.

Abbreviations: qRT-PCR, quantitative real-time PCR; CCK-8, Cell Counting Package-8; NC, adverse management.

Notes: (A) Expression of CENPK in BEL-7404 and SMMC-7721 cells was confirmed by qRT-PCR and Western blotting after transfection with shCENPK lentivirus or shNC. (B) Proliferation fee of BEL-7404 and SMMC-7721 cells was measured over 4 days by the CCK-8 assay. (C and D) Consultant photographs (C) and quantification (D) of the colony formation assays are proven for BEL-7404 and SMMC-7721 cells. (E) Evaluation of migration in BEL-7404 and SMMC-7721 cells as measured by wound therapeutic assays (×200). (F and G) Evaluation of invasion in BEL-7404 and SMMC-7721 cells as measured by transwell assays. (F) Consultant images (×200). (G) Variety of invaded cells was counted in 5 randomly chosen areas. Scale bar =100 μm. NC represents adverse management group (shNC), and shCENPK represents downregulation of CENPK group. *P<0.05, **P<0.01, ***P<0.001.

The authors apologize for this error and advise it doesn’t have an effect on the outcomes of the paper.

Read the original article

Creative Commons License
This work is printed and licensed by Dove Medical Press Restricted. The total phrases of this license can be found at and incorporate the Creative Commons Attribution – Non Commercial (unported, v3.0) License.
By accessing the work you hereby settle for the Phrases. Non-commercial makes use of of the work are permitted with none additional permission from Dove Medical Press Restricted, offered the work is correctly attributed. For permission for industrial use of this work, please see paragraphs 4.2 and 5 of our Terms.